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Abstract
Liver transplantation (LT) is a life-saving treatment for 
patients with end-stage liver disease and for patients 
with liver cell cancer related to liver disease. Acute and 
chronic liver diseases related to hepatitis viruses are 
between the main indications for liver transplantation. 
The risk of viral reinfection after transplantation is 
the main limiting factor in these indications. Before 
the availability of antiviral prophylaxis, hepatitis B 
virus (HBV) recurrence was universal in patients who 
were HBV DNA-positive before transplantation. The 
natural history of recurrent HBV was accelerated by 
immunosuppression, and it progressed rapidly to graft 
failure and death. Introduction of post-transplant 
prophylaxis with immunoglobulin alone first, and 
associated to antiviral drugs later, drastically reduced 
HBV recurrence, resulting in excellent long-term 
outcomes. On the contrary, recurrence of hepatitis 
C is the main cause of graft loss in most transplant 
programs. Overall, patient and graft survival after LT for 
hepatitis C virus (HCV)-associated cirrhosis is inferior 
compared with other indications. However, successful 
pretransplant or post transplant antiviral therapy 
has been associated with increased graft and overall 
survival. Until recently, the combination of pegylated 
interferon and ribavirin was the standard of care for the 
treatment of patients with chronic hepatitis C. Highly 
active antiviral compounds have been developed over 
the past decade, thanks to new in vitro  systems to 
study HCV entry, replication, assembly, and release. 
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Core tip: This review explores the available data in 
the literature concerning the treatment of hepatitis 
B virus and hepatitis C virus in the setting of liver 
transplantation in 2015. In particular, we will discuss 
regarding the possibilities to treat patients before and/
or after the transplantation. 
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INTRODUCTION
Liver transplantation (LT) is the only effective solution 
for patients with end-stage liver disease. Viral hepatitis 
B and C are among the most common causes of 
cirrhosis and hepatocellular carcinoma and the most 
frequent indications for liver transplantation. 
Introduction of post-transplant prophylaxis with 
immunoglobulin alone first, and associated to antiviral 
drugs later, drastically reduced hepatitis B virus (HBV) 
recurrence, resulting in excellent long-term outcomes. 
On the contrary, recurrence of hepatitis C is the main 
cause of graft loss in most transplant programs. New 
antiviral therapies have been recently introduced in the 
market, while former therapeutic approaches were far 
from optimal, because sustained virologic responses 
were only achieved in one-third of treated patients, 
and adverse effects were common and severe.
The following manuscript will discuss, in turn, the 
approach to management of HBV and hepatitis C virus 
(HCV) patients in the setting of liver transplantation. 
HBV IN LIVER TRANSPLANTATION
Despite massive vaccination campaigns, chronic 
hepatitis B (CHB) remains one of the most important 
causes of liver disease worldwide. About 25% of 
all chronic HBV carriers can develop serious liver 
diseases, such as chronic hepatitis, cirrhosis, and 
primary hepatocellular carcinoma[1], and HBV 
infection is responsible for a mortality rate of 2.7 
and 3.5 persons per 100000 inhabitants per year[2,3]. 
Furthermore, cirrhosis or hepatocellular carcinoma 
(HCC) due to HBV infection represented one of the 
most important indications for liver transplantation in 
the last ten years (14.4%), without a decreasing rate 
in respect of the previous decade[4]. The introduction of 
new antiviral therapies has dramatically changed the 
clinical scenario, because of the improvement obtained 
either in the pre-transplant setting and after LT. The 
management of hepatitis B surface antigen (HBsAg) 
positive transplant patients can be divided into the 
pre-transplant, prophylactic post-transplant and 
therapeutic post-transplant approach. Moreover, HBV 
prophylaxis is needed for LT recipients who receive 
graft from anti-hepatitis B core (HBc) positive donors.
Anti-HBV therapy in HBV decompensated cirrhosis
The aim of antiviral therapy is to reverse or delay 
complications of cirrhosis and the need for LT, and 
to decrease the risk of HBV re-infection in those 
who eventually undergo LT. Five oral nucleos(t)ide 
analogues (NAs) have been licensed for the treatment 
of CHB: three nucleoside [lamivudine (LAM), telbivudine 
(TBV), entecavir (ETV)] and two nucleotide [adefovir 
dipivoxil (ADF) and tenofovir disoproxil fumarate 
(TDF)] analogues[5]. Antiviral therapy should be started 
immediately in patients with HBV decompensated 
cirrhosis, regardless level of detectable serum HBV 
DNA and/or ALT activity. LAM (100 mg/die) was 
the first NA approved for treatment of CHB and its 
efficacy has been confirmed in randomized controlled 
trials and cohort studies showing stabilization or even 
improvement of liver function[6]. However, long-term 
LAM monotherapy is associated with progressively 
increasing rates of viral resistance due to YMDD 
mutations (15%-25% at year 1, 65%-80% at year 5)[7] 
and for these reason it is not currently recommended 
for patients with HBV decompensated cirrhosis. 
Furthermore, Lau et al[8] clearly demonstrated in 
27 CHB patients that the HBeAg positive special 
population was at higher risk of LAM resistance (48 
mo resistance 13/17 vs 1/10, P < 0.0011), due to a 
baseline higher HBV-DNA, (P < 0.1). ADF (10 mg/
die) was the second NA approved for the treatment 
of CHB. However, due to the risk of resistance during 
long-term therapy in naive patients (29% at year 5), 
higher costs and worsening of renal function[9], it has 
been replaced by tenofovir, which is a more effective 
and cheaper NA. TBV is a potent nucleoside analogue, 
however, its use in CHB monotherapy is still associated 
with selection for YMDD mutations[10]. For these 
reasons, the role of telbivudine monotherapy in the 
treatment of HBV decompensated cirrhosis is unclear 
due to its unfavorable resistance profile compared 
to ETV and TDF; they are the newer potent NA with 
a minimal or even no risk of resistance[11], thus are 
currently considered the treatment of choice in patient 
with decompensated liver cirrhosis. Anyway, ETV 
monotherapy is not a good option for patients with 
lamivudine resistance, as HBV resistance develops in 
approximately 50% of lamivudine resistant patients 
after five years of ETV treatment[12]. Regarding NA 
side effects, lactic acidosis has been reported in small 
group of patients treated with ETV[13] and even thought 
similar rates of renal adverse events has been reported 
in patients treated with TDF or ETV, renal function 
should be carefully monitored[14].
Referral for liver transplantation
Patients with HBV infection are listed for LT for three 
main causes: presence of HCC within Milan criteria and 
well-compensated liver function; decompensated liver 
function, with or without development of HCC; acute 
liver failure or fulminant hepatitis. 
HBV decompensated liver cirrhosis
Patients with HBV decompensated cirrhosis should be 
referred for LT[15]. While waiting for LT, the patients 
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should be monitored carefully at least every 3 mo for 
virologic response and possible virologic breakthrough 
in order to achieve serum HBV DNA undetectability[16]. 
In patients treated with lamivudine monotherapy 
levels of baseline HBV DNA have been independently 
associated with the outcome. In the same prospective 
multicenter study including 154 LAM-treated patients 
with HBV decompensated cirrhosis, most of the deaths 
(78%) occurred within the first 6 months suggesting 
that LAM may not be able to reduce the short-term 
mortality or the need for LT in patients with very 
advanced liver failure[17]. In contrast, initiation of 
antiviral therapy at earlier stages is associated with 
better chances of liver function recovery, since clinical 
benefit may take 3-6 mo. Whether these results are 
still valid with the current more potent anti-HBV agents 
is not clear. ETV and TDF are currently considered the 
treatments of choice in this group of patients, due to 
safety, tolerability, and efficacy; moreover, Buti in a 
systematic review demonstrated the cost-effectiveness 
of this new therapeutic alternatives[18]. In detail, ETV 
and TDF were considered safe, well tolerated and 
effective, as reported in a landmark study on 112 
patients by Liaw et al[14]. Moreover, Chang et al[19] 
in 2010 demonstrated an histological improvement 
on 96% of 57 patients after 3-years therapy with 
ETV, showing that the reversal of cirrhosis could 
be an achievable goal with new NA. An immediate 
consequence of this histological improvement is 
the reduction of MELD score: Peng et al[20] in 2012 
analyzed that the reduction of MELD score after oral 
therapy was about 2 points analyzing studies on oral 
therapies in HBV decompensated patients. Finally, a 
recent retrospective study on 5374 patients with CHB, 
demonstrated that ETV therapy was associated with a 
significantly lower risk of death or transplantation than 
LAM (HR = 0.42; 95%CI: 0.31-0.57; P < 0.001)[21]. 
Current guidelines state that in all decompensated 
patients lifelong treatment with ETV or TDF should be 
introduced, unless contraindicated[5]. The last point 
to highlight for patients awaiting LT is monitoring 
the effectiveness in the context of recurrence of HBV 
infection after LT. The main goal remains to reduce 
viral load under 100000 copies/mL before surgery, 
as demonstrated by Marzano et al[22] in a landmark 
study in 2005, in which the recurrence rate amongst 
recipients with pre-transplant viral load higher than the 
above mentioned values was extremely higher (50% 
and 0%, respectively). For these reasons, especially 
in those patients with long term therapy with LAM 
and listed for LT, the viral load should be carefully 
monitored. 
Hepatocellular carcinoma
The incidence of HCC in CHB is estimated to be 
different between treated and untreated patients, 
ranging from 2.8% to 6.4%, respectively[23]. Two main 
factors contribute to development of HCC in CHB, 
which is 100-fold higher than in non infected: first, 
the viral replication, whose load was strictly connected 
with the risk of HCC - independently of HBeAg antigen, 
presence of liver cirrhosis and serum ALT level - in a 
large coohort of Taiwanese patients[24]; second, the 
cytokine release mediated by the immune response, 
which ensures acceleration of hepatocyte cell cycles 
and genetic alterations[25]. Available treatments for 
HBV infection were demonstrated to be effective in 
reducing oncogenic damage due to HBV replication 
and integration. In a recent paper, Vlachogiannikos 
reviewed the most important metanalysis which 
evaluated the role of antiviral therapy among HCC 
development[26]. Interestingly, six metanalysis[23,27-31] 
agreed that the use of NAs or IFN-based regimes 
were effective in reducing the risk of HCC, but 
relevant issues about the benefit on different ethnic 
backgrounds and presence of absence of cirrhosis 
were not completely cleared; the authors stated that 
the higher risk coohort - cirrhosis - could reach the 
higher benefit from treatment. Nervertheless, the 
reduced risk of decompensation of liver disease could 
not be counterbalanced by a similar reduction of the 
risk of HCC development; thus all the patients, treated 
and untreated, have to perform six-months active 
surveillance. 
Acute-fulminant hepatitis B
In patients with acute liver failure due to acute or 
acute-on-chronic hepatitis B the treatment strategy 
remains not well defined. In case of fulminant 
hepatitis, specific supportive care is still considered 
the treatment of choice, even though efficacy of NA, 
and in particular LAM, has been already proved for 
prevention of post-transplant recurrence[32]. In the 
latter setting, acute flare in chronic HBV infection is 
mainly noted amongst immunosuppressed patients 
or in patients taking immunomodulant drugs, as 
anti-TNF alfa or monoclonal antibodies; in those 
who require LT, introduction of lamivudine in naive 
patients, or treatment modification with another NA 
if mutations have been identified, could be a rational 
approach[33]. On the other side, trials assessing the 
efficacy played by newer antivirals seem to be very 
difficult to perform and only few cases are currently 
reported in literature[34,35]. In a prospective study, Chen 
et al[36] demonstrated that treated patients with acute-
on-chronic liver failure experienced better long-term 
survival than untreated ones (64.7% vs 36.2%, P = 
0.006), even though in the first three months there 
were no difference between the cohorts.
Prevention of recurrence after LT
The introduction of newer therapies has reduced 
the recurrence of HBV infection after LT, which was 
considered a major problem in the past, because 
of severe reduction of graft and patient survival. 
These encouraging data were also confirmed by a 
recent study published on the ELTR registry, which 
stated that disease recurrence is going to be no 
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survival P = 0.005; RR = 0.17; 95%CI: 0.05-0.28). 
Interestingly, the Authors showed that the efficacy 
of HBIg administration was demonstrated only in the 
subgroup of patients who were HBV-DNA positive 
before LT (P < 0.001; RD = 0.42; 95%CI: 0.32-0.52). 
If the results were confirmed, the use of HBIg should 
be limited only in high selected or limited fields, 
even though the difference in survival has not been 
confirmed when evaluating long term follow-up. Other 
Authors recently proposed an "on-demand therapy", 
personalized on the individual risk: for instance, 
Cholongitas demonstrated in a prospective study that 
28 patients with HBV DNA levels undetectable before 
LT were safely treated against HBV infection with 6 mo 
therapy with HBIg and then with monotherapy with 
TDF or ETV[43]. Also Hu in a recent study demonstrated 
that on demand dose HBIg (adjusted for anti-HBs titer) 
plus ETV were efficient in preventing HBV recurrence, 
which developed only in 2/145 (1.37%) patients[44]. 
The choice between TDF or ETV should depend only on 
the presence of LAM resistance before transplant: in 
this case, TDF should be preferred. 
Two more factors should be considered when 
choosing the best therapy for HBV transplanted 
patients: costs and adherence; in fact, in a retro-
spective study, Chang et al[45] demonstrated that 
non-compliance to HBIg was equal to 14% in a small 
cohorts of LT patients, and that also amongst these 
patients anti-HBs titers were satisfactorily achieved. 
For these reasons, many studies assessing the efficacy 
of monotherapy have been published[46], but more 
efforts to investigate stronger risk factors of recurrence 
and to individualize treatment should be performed. 
Lastly, vaccination after LT has been investigated 
and used as a prophylactic tool against HBV recurrence. 
It was currently used either in pre and in the post 
transplant setting before introduction of HBIg[47]. 
In a pilot study performed in 2000, Sanchez Fueyo 
et al[48] demonstrated that HBV vaccination after 
1-year therapy with HBIg was useful and cost-
effective in a small cohort of 16 selected patients, 
who were transplanted for cirrhosis or fulminant HBV 
hepatitis. However, at present long term follow-up 
data evaluating this strategy amongst large cohorts of 
patients are still missing. 
Treatment of recurrence after LT
In those patients who experience post-LT HBV reac-
tivation (for non compliance, viral mutations), viral 
recurrence determines the rapid development of severe 
liver dysfunction, comprising graft loss and death. 
Fortunately, huge cases of fibrosing cholestatic hepatitis 
due to HBV after LT are rare[49]. The role of TDF or 
ETV for the treatment of recurrence seems to be 
optimal, but two main aspects have to be considered: 
first, HBV mutation: patients who experience post-
LT HBV reactivation during LAM therapy should 
be treated with TDF instead of ETV; second: renal 
function, which is a major problem in all LT patients 
longer a significant cause of death/graft loss. HBV 
decompensated patients had a significantly better 
patient and graft survival at 1, 3, 5, and 10 years (83%, 
78%, 75%, and 68% and 80%, 74%, 71%, and 64% 
respectively), compared to HBV/HCC patients (84%, 
73%, 68%, 61%, and 81%, 70%, 65%, and 58%; P 
= 0.001 and P = 0.026 respectively)[37]. If untreated, 
recurrence after LT is universal and its association with 
rapidly progressive hepatitis that jeopardizes long-
term patient and allograft survival. In fact, recurrence 
is initially characterized by serum HBsAg and HBV-DNA 
reappearance, and followed by biochemical, histological 
and clinical evidence of recurrent liver disease.
A multicentric study published in 1993 by Samuel 
investigated risk factors for recurrence among 201 LT 
recipients with HBV-related cirrhosis from 17 Centers 
in Europe. Long-term Immunoglobulin administration 
(P < 0.01), HBV-DNA negativization before LT (P < 
0.05), and the abscence of HBeAg before LT (P < 0.001) 
were evaluated as major factors against recurrence 
at multivariate analysis[38]. More rencently, Xu et al[39] 
identified pre-transplant HBV DNA level, presence 
of HCC, antiviral treatment and post transplant viral 
mutation as the major risk factors associated with 
recurrence after LT. However, the first point is matter 
of debate. Analyzing data from ELTR registry, the 
proportion of recipients with HBV-DNA negative at LT 
progressively decreased (from 81.2% to 51% and 
from 82% to 57.4% in HCC patients, respectively; 
each P < 0.001), without statistical difference in terms 
of patient and graft survival. Initially, prophylaxis 
against HBV re-infection was successfully performed 
with anti-HBV immunoglobulins (HBIg), as showed 
by Samuel et al[38] in 1993, and then with the use of 
LAM in a pilot study provided in 1996 by Grellier[40]. 
Then, other NAs have been tested after LT, with good 
results. At present, LAM and/or ADV in combination 
with HBIg are still considered the treatment of choice 
for prevention of HBV re-activation, since they reduced 
the risk of graft infections to less than 10%[5]. 
Costs, patient’s compliance and viral mutation 
represent the most intriguing factors which lead 
clinicians to find the optimal type of treatment. A meta-
analysis published by Katz et al[41] in 2010 analyzed 
ten studies which compared the combination therapy 
(NA + HBIg) and mono-therapy with LAM or ADV: 
treatment with HBIg and LAM was demonstrated to be 
better than HBIg alone in reducing HBV recurrence (RR 
= 0.28; 95%CI: 0.12-0.66, 10 studies, I2 = 60.7%) 
and HBV DNA levels (RR = 0.21; 95%CI: 0.04-0.98, 
I2 = 0%), all-cause mortality (RR = 0.44; 95%CI: 
0.25-0.77, I2 = 6.4). More recently, Wang et al[42] 
performed a systematic review which demonstrated 
that, evaluating a total of 1484 patients of seventeen 
studies, treatment with HBIg reduced HBV recurrence 
(P < 0.001; RR = 0.16; 95%CI: 0.12-0.20) and viral 
mutations (P < 0.001; RR = 3.13; 95%CI: 1.86-5.26), 
and improved patient's early survival (1-year survival 
P = 0.03; RR = 0.08; 95%CI: 0.01-0.15; 3-year 
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due to immunosuppression, aging, pre-transplant 
hepatorenal syndrome. TBV was demonstrated to 
be effective in improving renal function: in a recent 
prospective study by Cholangitas et al[50], 17 patients 
who received TBV after 12 mo of standard therapy 
presented a significant improvement of renal function 
if compared to controls. Another retrospective study 
highlighted a significant decrease of eGFR in CHB 
patients after 17 mo treatment of TDF (P < 0.001), 
with a recurrence rate of 0%; TDF was considered 
a risk factor at multivariate analysis together with 
diuretic treatment and chronic renal failure[51]. This 
study showed data similar to what reported in TDF-
treated HIV population, who have experienced a time-
dependent impairment of renal function (P < 0.007)[52], 
even though contrasting data and confounding factors, 
as multiple drugs co-administration, have to be taken 
into account. In this setting, some new trials focused 
on LT population and comparing effectiveness about 
HBV recurrence and renal function between ETV and 
TDF, should be encouraged. 
Prophylaxis of patients who receive livers from anti-HBc 
positive donors
Anti-HBc grafts represent a major source of organs 
worldwide, having a prevalence ranging from 10% to 
50% in endemic HBV areas[53]. Use of anti-HBc graft 
is considered safe, since it does not affect graft or 
patient survival[54,55]. However, patients who receive 
these organs have an increased risk of de novo HBV 
infection; however, this is not the only way to develop 
a de novo HBV infection after LT: for instance, a recent 
study published by Xie et al[56] highlighted that occult 
HBV infection had a prevalence of > 40% in alcohol 
related liver transplanted recipients.
There is some debate on the optimal strategy 
after liver transplantation when anti-HBc organs are 
allocated. The current guidelines recommend indefinite 
prophylaxis with LAM for HBsAg negative recipients[5]. 
This recommendation was retrieved by a landmark 
study made by Cholongitas et al[57], who reviewed the 
entire literature of the field. The Authors confirmed 
the need to allocate the anti-HBc organs preferentially 
to HBSAg positive or anti-HBc positive donors, but 
also stated that the risk of HBV infection after LT can 
be higher than 40% without prophylaxis. The study 
provided also interesting data regarding treatment: 
if vaccination alone seemed to be ineffective (100% 
infection rate), combination therapy with LAM + HBIg 
seemed inadequate, due to costs, compliance and 
good results provided by LAM monotherapy (2/75, 
2.6% of infection rate). Interestingly, the Authors 
proposed an algorithm for therapy which takes 
into account the serological status of the recipient, 
assessing the need to combined therapy with HBIg and 
LAM only in antiHBc donor/HBSAg Recipient matching. 
Similarly, Brock et al[58], analyzing 958 patient from 
UNOS database, demonstrated that use of HBIg alone 
could confer less risk of mortality if compared to 
LAM therapy; notwithstanding, costs and absence of 
significance about HBV-associated graft failure seemed 
to discourage this therapeutic alternative. 
HDV IN LIVER TRANSPLANTATION
HDV coinfection has a variable prevalence among CHB 
patients. In a recent Chinese study, 426 out of 6604 
patients were positive for HDV IgM[59]. The coinfection 
is a known risk factor for end-stage liver disease, 
thus the main goal in such patients is represented by 
suppression of HDV replication. However, treatment 
options are very limited, because NAs used for the 
treatment of HBV are ineffective and decompensated 
cirrhosis could not benefit from IFN based regimens. 
Thus, LT often remains the main choice in this setting[60]. 
Coinfection has remained a stable indication for LT in 
the last two decades, having a prevalence of 2%[4]. 
Furthermore, analyzing data from ELTR Registry, HDV 
co-infection was associated with better short and 
long term patients survival (1-5-10 years survival: 
92%, 89%, 86%, and 83%,75%, 60%, each P < 
0.001); These data were confirmed also for grafts 
(1-5-10 years graft survival: 81%, 85%, 80%; 80%, 
71%,64%; each P < 0.001). The better survival 
amongst coinfected patients is presumably due to 
inhibition of HBV replicative cycle performed by 
HDV[37]. Conversely, no difference in terms of patients 
and graft survival was seen among patients with HCC. 
HCV IN LIVER TRANSPLANTATION
Nowadays, cirrhosis secondary to chronic hepatitis 
C, with or without hepatocellular carcinoma, is 
the leading indication for LT worldwide. Recurrent 
hepatitis C infection of the allograft is universal if HCV 
is detectable at the moment of transplant surgery. 
Approximately one third of the patients will progress 
to liver cirrhosis in the graft within only 5 years after 
transplantation and, subsequently, graft and patient 
survival are significantly worse in patients undergoing 
LT for HCV-related cirrhosis than in those transplanted 
for other causes[61,62]. Two strategies, including pre-
transplant treatment of HCV infection in cirrhotic 
patients and post transplant treatment of liver graft 
infection, can be adopted for achieving sustained 
virological response (SVR), virus eradication and finally 
improving clinical outcomes of HCV-infected recipients. 
Antiviral treatment in waiting list for liver transplantation
The aim of antiviral treatment while on the waiting 
list is to achieve either an SVR or an on-treatment 
undetectable HCV-RNA at time of transplantation to 
avoid HCV infection of the graft. Few studies have 
shown that peg-IFN + ribavirin (RBV) treatment can 
prevent graft infection in patients who achieve viral 
clearance (undetectable HCV-RNA) during therapy 
before LT[63,64]. As expected, response rates are mainly 
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influenced by genotype (better results in non-G1 
patients) and, in those patients who achieve viral 
clearance, it appears that duration of treatment may 
be relevant (> 16 wk of therapy is associated with 
prevention of graft infection after LT)[63]. Overall, 
efficacy of this therapy was suboptimal (30% of SVR 
rates). 
The first direct acting antivirals (DAAs) approved in 
2011, the protease inhibitors telaprevir and boceprevir, 
increased the efficacy of Peg-IFN-RBV, both in cirrhotic 
patients treated in waiting list (WL) (pTVR up to 
67%), as well as in transplant recipients (SVR12 up 
to 62%). In HCV-infected patients awaiting LT limited 
data were reported. Verna et al[65] showed results of 
triple therapy in a small series of HCV-infected G1 
cirrhotics (n = 20) in the waiting list for LT; patients 
underwent therapy for a median time of 14 wk. Most 
of them were previous non responders, 20% had 
ascites and 45% had a hepatocellular carcinoma at 
the time of treatment initiation. Post-transplant SVR12 
was 67% (8 out of 12 transplanted patients). From 
safety point of view, serious adverse events occurred 
in nine patients (31%), including one death (3%) 
and 8 hospitalizations (28%). Despite these results, 
the proportion of patients on the waiting list that 
may benefit from triple therapy with telaprevir (TPV) 
or boceprevir (BOC) is small, for several reasons: 
in decompensated patients IFN-based therapies are 
contraindicated, efficacy rates are very low in cirrhotic 
patients who are previous null-responders to PR (a 
common situation in patients awaiting LT) and PI-
based regimens in real-life compensated cirrhotic 
patients are associated with serious adverse events 
and even death[66]. More importantly, with the recent 
approval of IFN-free regimens, the use of boceprevir 
and telaprevir are no longer recommended[67]. 
The use of DAAs has been a step forward in the 
treatment of chronic hepatitis C. The combination of 
several of these drugs in the absence of interferon 
(IFN-free regimens), has shown high SVR rates and 
a significantly better tolerance when compared with 
IFN-containing regimens. The results from the first 
clinical trial including patients in waiting list for LT 
treated with an IFN-free regimen, was the proof of 
concept that eradicating HCV before LT is possible in a 
large proportion of patients[68]. In this phase 2, open-
label study, 61 patients with HCV of any genotype and 
cirrhosis (Child-Turcotte-Pugh score, ≤ 7) who were 
on waiting list for LT for HCC, received up to 48 wk 
of Sofosbuvir (SOF) and RBV before LT. Thus, 70% 
of transplanted patients treated with SOF and RBV 
during the WL, who had HCV-RNA levels < 25 IU/L 
prior to transplant, get SVR 12 wk after LT. All patients 
included in this study had compensated cirrhosis 
and hepatocellular carcinoma, as indication for 
transplantation. Importantly, the time of RNA target 
not detectability before LT (> 30 d) has emerged as 
the only crucial factor for preventing HCV recurrence. 
Data from clinical trials and real-life cohorts 
including compensated or decompensated cirrhotic 
patients not in waiting list are very encouraging, as 
high safety and efficacy can be obtained with several 
regimens. The safety and efficacy of the combination 
Sofosbuvir and Simeprevir (SIM) with or without 
RBV was assessed in COSMOS trial[69] and in large 
real-life cohorts. In the primer, the combination was 
assessed for 12 or 24 wk in 167 G1 patients including 
80 previous null responders without significant fibrosis 
(F0-2) and 87 treatment naïve or prior null responders 
with significant fibrosis (F3-4). The global SVR rate was 
92% and remained high (93%) when decompensated 
cirrhotic patients (n = 41) were considered separately. 
In the TRIO network real-life cohort[70], the subgroup 
of patients with cirrhosis (n = 125) achieved SVR rates 
of 75%, significantly lower than non cirrhotic patients. 
Another high efficacious IFN-free regimen is the 
fixed-dose combination of sofosbuvir and ledipasvir, 
that was explored in three large clinical trials of G1 
patients (ION-1, ION-2 and ION-3). The ION-1 and 
ION-2[71,72] evaluated this combination with or without 
RBV in G1 treatment-naïve and experienced patients, 
respectively. In both studies SVR rate was excellent, 
irrespectively of the presence of cirrhosis. Moreover, 
a pooled integrated analysis including of all the G1 
cirrhotic patients (n = 513) treated with Sofosbuvir 
plus ledipasvir (LDV) along the phase Ⅱ and Ⅲ trials 
was conducted[73]. In naïve cirrhotic patients (n = 
161), neither treatment duration nor RBV use showed 
to have a significant impact on SVR12 (96%-100%). 
Regarding treatment-experienced cirrhotic patients (n 
= 352), 90% of patients achieved SVR12 after 12 wk 
without RBV, 96% after 12 wk with RBV, 98% after 
24 wk without RBV, and 100% after 24 wk with RBV, 
suggesting a beneficial role for RBV or extension of 
treatment duration in this group. 
A phase Ⅱ, randomized, prospective, multicenter 
trial, using fixed-dose combination of SOF + LDV 
plus RBV for 12 or 24 wk in treatment-naıve and 
treatment-experienced patients with GT1 or four and 
decompensated liver disease who were awaiting LT, 
was recently reported[74]. The exclusion criteria were 
as follows: Child-Pugh scores from 13 to 15; history 
of major organ transplant, including liver; presence of 
HCC; total bilirubin ≥ 10 mg/dL; hemoglobin ≤ 10 
g/dL; creatine clearance ≤ 40 mL/min; and platelets 
≤ 30000. Fifty-three patients were treated for 12 wk, 
including 30 CTP B and 23 CTP C patients, while 55 
patients were treated for 24 wk, including 29 CTP B 
and 26 CTP C patients. Patients were predominantly 
male (67%), Caucasian (93%), and had been 
previously treated for HCV (65%). Mean baseline HCV-
RNA was 5.8 log10 IU/mL range 3.2-7.1 log10 IU/mL. 
Twenty-eight patients (26%) had a MELD score > 15. 
At baseline, 96% of CPT class C patients had ascites 
and 88%-91% encephalopathy, in the 12- and 24-wk 
arms, respectively. Overall, the SVR12 was 87% 
and 89% for the patients treated for 12 and 24 wk, 
respectively. No significant difference was observed 
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for the CTP B patients (87% vs 89%) or for the CTP 
C patients (86% vs 90%). Biochemical and clinical 
improvement of the patients with successful HCV 
therapy (documented by an improvement in MELD 
score as well as an increase in serum albumin) was 
reported. However, clinical condition of some patients 
stabilized, while it worsened in other patients, meaning 
that cirrhosis was already too advanced to improve 
despite obatining SVR. 
Administration of LDV/SOF + RBV in patients with 
decompensated cirrhosis has been evaluated in US 
(SOLAR 1) and Europe, Canada, Australia and New 
Zealand (SOLAR 2), the largest study of such patients 
to be evaluated to date[75]. Amongst patient with Child 
B liver cirrhosis SVR4 was observed in 24/28 patients 
(86%) and 11/11 patients (100%) in 12 and 24 wk 
arms, respectively. 14/16 patients (88%) and 3/6 
patients (50%) Child C patients achieved SVR4 in 12 
and 24 arms, respectively. In the same cohort the drug 
safety was evaluated. Among 215 patients with liver 
cirrhosis (117 Child B and 98 Child C) only 22 (Child B) 
and 35 (Child C) experienced serious adverse events, 
mainly anemia due to RBV.
Safety and efficacy of 12-wk combination regimen 
with daclatasvir and sofosbuvir in patients with 
advanced liver disease were recently presented[76]. 
If the patients were transplanted during treatment 
they could receive 12 wk of extended treatment 
immediately posttransplant, regardless of treatment 
duration before transplant. Sixty patients with liver 
cirrhosis were included of whom 40% were treatment-
naive and 75% G1. The prevalence amongst Child-
Pugh classes was 20% A, 53% B, and 27% C. MELD 
score ranged from 8 to 27. Overall, 83% of patients 
in the cirrhosis cohort achieved SVR12, with higher 
SVR12 rates in patients with Child-Pugh class A or B 
disease than in those with class C. SVR12 rates were 
comparable regardless of prior treatment experience 
or baseline demographic characteristics. Four cirrhotic 
patients received a liver transplant during treatment; 
3 of 4 extended treatment posttransplant and all 4 
achieved SVR12. The most common AEs (any grade) 
were headache, fatigue, anemia, diarrhea, and nausea, 
without serious ones. 
The clinical and biochemical improvements experi-
enced by decompensated cirrhotics who achieved SVR 
take on great relevance in LT setting, as some patients 
may be delisted and improve their quality of life. So far 
this event has been reported only as anecdotal case[77], 
concerning a 67-year old woman who was listed for 
LT for decompensated cirrhosis (CTP 12, MELD 16), 
refractory ascites, and chronic encephalopathy. After 
successful treatment with Sofosbuvir and Ribavirin and 
SVR12, liver function and clinical status improvement 
allowed for her to be removed from the liver transplant 
waiting list. At the present time, criteria for de-listing 
patients have not been identified yet, and a successful 
treatment before LT is not always correlated to a 
clinical and biological improvement. Patients with 
advanced liver disease and high MELD scores will 
probably not benefit from a viral clearance. However, 
it is true that in the next years the availability of 
interferon-free highly effective therapies of HCV 
infection promise to bring about a ‘revolution’ in the 
field of end-stage liver disease, as did NAs in patients 
with HBV infection, representing a life-saving therapy 
that could also reduce the burden of patients needing 
liver transplantation. Efficacy results from clinical trials 
cannot be totally translated to waiting list scenario, 
being the waiting time unpredictable and the treatment 
duration as well. More results from clinical trials will be 
needed for allowing a better selection of patients who 
have higher chance to eradicate HCV before receiving 
a new liver. Anywise, for those patients in whom 
treatment in waiting list will not be efficacious a good 
option is the post-transplant antiviral treatment.
Antiviral treatment after liver transplantation 
One of the main characteristics of hepatitis C recurrence 
after LT is the accelerated course of the disease when 
compared to immunocompetent patients[78-80]. This 
accelerated fibrosis rate impacts both the allograft and 
recipient survival, which is significantly reduced when 
compared with non-HCV liver recipients[81]. It is well 
established that the presence of significant fibrosis 
in the graft (F ≥ 2, METAVIR)[82,83] or significant 
portal hypertension (HVPG ≥ 6)[84] one year after 
LT identifies patients with aggressive hepatitis C 
recurrence. The most common approach to treat 
hepatitis C after LT has been to start Peg-IFN + 
RBV once histological damage is confirmed in the 
graft. Overall SVR rates with combined therapy were 
low, ranging between 30% to 40% across different 
series, which have been combined thereafter in three 
systematic reviews[85-87]. These poor virological results 
were mainly explained by high rates of treatment 
discontinuation, dose reductions and poor tolerance 
or adverse events. Despite these results, the positive 
impact of SVR on survival was well demonstrated. 
Patients achieving SVR after LT have better survival 
curves compared to non-responders, as shown by 
Berenguer et al[85]. Carrion et al[88] also demonstrated 
the positive impact of SVR on HVPG when performed 
before and after antiviral treatment: portal pressure 
decreased or stabilized in responders compared to non 
responders, in whom HVPG increased rapidly overtime. 
Regarding triple therapy with PIs in the post-LT 
setting, several studies have evaluated the safety 
and efficacy of such regimens in liver transplant 
recipients[89,90]. Most of the patients had an advanced 
fibrosis stage (METAVIR F ≥ 2) or cholestatic HCV. 
SVR12 rates ranged between 48% and 62%[91,92]. 
Even though the addition of PI to PEG/RBV increased 
SVR rates, the major drawbacks of triple therapy in LT 
recipients were the high rate of severe adverse events 
leading to treatment discontinuation and drug-drug 
interactions especially with immunosuppressive drugs.
In the last year, multicentric clinical trials, com-
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passionate use programs and real-life cohorts combining 
oral DAAs for treating HCV-infected liver transplant 
recipients have reported very good SVR12 rates, 
ranging from 70% to 96%. The first multicenter, 
open-label pilot study including transplant recipients 
assessed the safety and efficacy of the combination 
of sofosbuvir and ribavirin for 24 wk[93]. The cohort 
included 40 patients, 40% of them with cirrhosis. 
SVR12 rate was 70%. The excellent efficacy and safety 
profile of this regimen was confirmed from sofosbuvir 
compassionate use program results. Fifty-nine percent 
of patients, who received up to 48 wk of sofosbuvir 
and ribavirin, with or without pegylated Peg-IFN, 
achieved SVR12. Importantly, those with a cholestatic 
hepatitis C (including fibrosing cholestatic hepatitis) 
showed higher viral responses (SVR 73%) compared 
to patients with cirrhosis (SVR 43%)[89]. 
The combination of LDV-SOF-RBV has demonstrated 
high rates of SVR in a part of the SOLAR-I study. 
Recipients infected with HCV genotype 1 or 4 received 
this combination for 12 or 24 wk[94]. In patients with 
Child-Pugh class B or C, there was a reduction in 
SVR rates as compared to patients with mild disease. 
Specifically, among individuals with Child-Pugh C class, 
the SVR rates were 60% and 67%, respectively. Of 
note, the number of patients included was very small (8 
total across the 2 arms).
The combination of SOF and SIM was assessed 
in 68 liver transplant recipients included in the real-
life HCV TARGET study[90]. The overall SVR4 rate was 
90%, that remained higher in cirrhotic patients (86%). 
The efficacy and safety of this combination was 
investigated in another real-life study[95] that showed 
excellent results: 91% of liver transplant recipients 
achieved an SVR12 after receiving 12 wk with or 
without RBV. In both studies slower SVR12 were 
showed in subtype 1a than subtype 1b patients (83% 
vs 95%, respectively; and 88% vs 96% respectively. 
Most importantly in the later study all failures in F3-F4 
patients were in subtype 1a patients. 
The open-label phase Ⅱ CORAL-I study[96] assessed 
treatment with 24 wk of ombitasvir/paritaprevir/
ritonavir with dasabuvir and ribavirin in a cohort of 
34 orthotopic liver transplantation recipients with a 
METAVIR score of 2 or less and recurrent genotype 1 
HCV infection. The SVR12 rate was excellent (97%). 
Even though small data are available for daclatasvir 
(DAC) combined with SOF or SIM, mostly from real-life 
cohort and compassionate use programs, high rates 
of SVR were observed in patients with post transplant 
HCV recurrence treated with these combinations[97-99]. 
From a safety point of view, very few severe 
adverse events were reported so far throughout 
studies. Most deaths occurred in cirrhotic patients 
were drug-unrelated. Regarding drug interactions, 
neither SOF nor LDV showed any important drug-
drug interactions with the calcineurin inhibitors. 
Conversely, because of significantly increased plasma 
concentrations of SIM, the concomitant use of SIM and 
cyclosporine is not recommended in liver transplant 
recipients. Using the combination of ritonavir-boosted 
paritaprevir, ombitasvir, plus dasabuvir with ribavirin 
adjusted doses of tacrolimus and cyclosporine are 
needed. 
CONCLUSION
Viral hepatitis, such as HBV and HCV, is still the largest 
indication for liver transplantation. 
The antiviral therapy with NA - especially with TDF 
or ETV - represent the most efficacious therapy for 
HBV related cirrhotics awaiting liver transplantation, 
in whom the viral load should be carefully evaluated. 
Continuation therapy after LT, adding HBIg, minimize 
the risk of HBV recurrence. Liver grafts from anti-
HBc positive donors can be safely used, also in HBsAg 
negative recipients, preferentially anti-HBc/anti-
hepatitis B surface antibody positive ones.
To prevent HCV recurrence after LT, the ideal 
strategy might be to achieve HCV eradication before 
transplant, having more than 30 d of HCV-RNA TDN. 
However, data on patients who are in the waiting list 
are still scarce, and in special population (i.e., seriously 
ill recipients, HCC), the choice to start treatment 
of HCV before the transplant have to be carefully 
evaluated; furthermore, several DAAs regimens are 
now available for successfully treat patients who 
experience HCV recurrence after LT. As we become 
more experienced in treating these patients, we will 
gain more information about which patients would 
benefit from treatment before transplantation and 
for which patients it would be best to treat after 
transplantation.
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